Since Halozyme Therapeutics Inc. (NASDAQ:HALO) and CRISPR Therapeutics AG (NASDAQ:CRSP) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation of both companies.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Halozyme Therapeutics Inc.||18||-1.95||144.71M||-0.27||0.00|
|CRISPR Therapeutics AG||59||0.00||34.37M||-0.46||0.00|
Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Halozyme Therapeutics Inc. and CRISPR Therapeutics AG.
Table 2 provides us Halozyme Therapeutics Inc. and CRISPR Therapeutics AG’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Halozyme Therapeutics Inc.||813,434,513.77%||-15.8%||-9.6%|
|CRISPR Therapeutics AG||58,512,087.16%||-2.6%||-2%|
The current Quick Ratio of Halozyme Therapeutics Inc. is 2.8 while its Current Ratio is 3.2. Meanwhile, CRISPR Therapeutics AG has a Current Ratio of 8.3 while its Quick Ratio is 8.3. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Halozyme Therapeutics Inc.
The next table highlights the delivered recommendations and ratings for Halozyme Therapeutics Inc. and CRISPR Therapeutics AG.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Halozyme Therapeutics Inc.||0||2||2||2.50|
|CRISPR Therapeutics AG||0||0||3||3.00|
$20.75 is Halozyme Therapeutics Inc.’s average target price while its potential upside is 9.67%. Competitively the average target price of CRISPR Therapeutics AG is $72, which is potential 9.39% upside. Based on the analysts view we can conclude, Halozyme Therapeutics Inc. is looking more favorable than CRISPR Therapeutics AG.
Insider and Institutional Ownership
Roughly 87.2% of Halozyme Therapeutics Inc. shares are owned by institutional investors while 46.8% of CRISPR Therapeutics AG are owned by institutional investors. Halozyme Therapeutics Inc.’s share owned by insiders are 0.1%. Insiders Competitively, owned 0.4% of CRISPR Therapeutics AG shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Halozyme Therapeutics Inc.||-1.19%||12.57%||20.73%||23.85%||23.29%||30.96%|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
For the past year Halozyme Therapeutics Inc.’s stock price has smaller growth than CRISPR Therapeutics AG.
On 7 of the 12 factors CRISPR Therapeutics AG beats Halozyme Therapeutics Inc.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.